Andrew G. Long
2017 - INSYS Therapeutics
In 2017, Andrew G. Long earned a total compensation of $1M as Chief Financial Officer at INSYS Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $86,000 |
|---|---|
| Option Awards | $610,353 |
| Salary | $127,985 |
| Stock Awards | $149,550 |
| Other | $36,997 |
| Total | $1,010,885 |
Long received $610.4K in option awards, accounting for 60% of the total pay in 2017.
Long also received $86K in non-equity incentive plan, $128K in salary, $149.6K in stock awards and $37K in other compensation.
Rankings
In 2017, Andrew G. Long's compensation ranked 8,924th out of 14,666 executives tracked by ExecPay. In other words, Long earned more than 39.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,924 out of 14,666 | 39th |
Division Manufacturing | 3,408 out of 5,768 | 41st |
Major group Chemicals And Allied Products | 1,160 out of 2,074 | 44th |
Industry group Drugs | 924 out of 1,730 | 47th |
Industry Pharmaceutical Preparations | 726 out of 1,329 | 45th |
Source: SEC filing on April 16, 2018.
Long's colleagues
We found five more compensation records of executives who worked with Andrew G. Long at INSYS Therapeutics in 2017.
2017
Saeed Motahari
INSYS Therapeutics
Chief Executive Officer
2017
Franc Del Fosse
INSYS Therapeutics
General Counsel
2017
Darryl Baker
INSYS Therapeutics
Chief Financial Officer
2017
Santosh Vetticaden
INSYS Therapeutics
Chief Executive Officer
2017
John Kapoor
INSYS Therapeutics